Journal article
Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial
KM Field, EH Barnes, HW Sim, AK Nowak, J Simes, MA Rosenthal, H Wheeler, EJ Hovey, LM Cher
Journal of Clinical Neuroscience | Published : 2021
Abstract
Assessment of neurocognitive function (NCF) is important in brain tumor clinical trials, however there are varying methodologies available. We used the Cogstate computerized NCF testing battery and the mini-mental state examination (MMSE) to prospectively assess cognition in adult patients with recurrent glioblastoma (GBM) enrolled in the CABARET randomized phase II clinical trial of bevacizumab versus bevacizumab plus carboplatin chemotherapy. We determined completion rates; compared NCF results between trial arms; and assessed baseline NCF as a predictor of survival outcome. 93 of 103 eligible patients completed baseline Cogstate NCF testing. Completion rates were between 60 and 100% acros..
View full abstractGrants
Awarded by Bristol-Myers Squibb
Funding Acknowledgements
This study was funded by Roche Products, Pty Limited (Australia) with support also from the NHMRC Clinical Trials Centre (NHMRC Program Grant 1037786), and Cancer Australia Support for Cancer Clinical Trials Grant and CINSW Cooperative Clinical Trials Grant to COGNO. Specifically for this neurocognitive function sub-study: Roche did not have a role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and the decision.